Peptide Therapies – What Has Evidence, What Doesn't, and Why Sourcing Is the Real Issue

Peptide therapies are everywhere in biohacking circles. Subcutaneous injections of BPC-157, stacking CJC-1295 with Ipamorelin, Delta sleep-inducing peptide for deeper rest, running Epithalon for longevity. The discussions fill forums, Discord servers, and longevity podcasts. What’s harder to find is an honest accounting of what evidence exists, what doesn’t, and why the sourcing question matters more than which compound you pick.

This article gives you that accounting.

What Are Peptides and How Do They Work

Peptides are short chains of amino acids, shorter than proteins, typically 2 to 50 residues. Your body uses them as signaling molecules. Insulin is a peptide. So is oxytocin. So is growth hormone releasing hormone. They function like molecular keys that bind to specific receptors and trigger biological responses.

The therapeutic appeal is that specificity. Small molecules (traditional drugs) often have broad systemic effects. Peptides are more targeted, at least in theory. A peptide that mimics growth hormone releasing hormone tells the pituitary to release growth hormone. A peptide that binds to ghrelin receptors can stimulate GH release through a different pathway. The idea is that you can achieve fairly specific outcomes without the blunt-instrument effects of something like synthetic HGH.

The distinction from proteins matters practically: peptides are small enough to synthesize in a lab, relatively cheap to produce, and typically degrade quickly in the body. That degradation is both a safety argument and why most require injection. Oral bioavailability is poor for most peptides because digestion breaks them down before they can reach their targets.

The Evidence Hierarchy for Peptide Therapies

Not all peptides are equal. If you’re going to evaluate them rationally, you need a framework.

FDA-approved peptides with established clinical evidence. Several peptides have gone through the full regulatory process and have established medical uses. Sermorelin and tesamorelin are GHRH analogs approved for treating growth hormone deficiency and HIV-associated lipodystrophy respectively. Liraglutide (a GLP-1 analog) is prescribed for type 2 diabetes and obesity. Oxytocin is used in obstetrics. These have clinical trial data, known safety profiles, and legitimate prescribing pathways.

Peptides with clinical evidence outside approved uses. CJC-1295 and Ipamorelin have been tested in human studies. CJC-1295 (a modified GHRH analog) showed sustained GH elevation in a small clinical trial published in 2006. Ipamorelin, a ghrelin mimetic, has human pharmacokinetic data. The studies are small and not designed around long-term outcomes, but they exist. These aren’t pure speculation.

Animal-only evidence. BPC-157, TB-500, and KLOW sit here. BPC-157 and KLOW have impressive animal literatures: tendon healing, gut repair, CNS protection, reduced inflammation across dozens of rodent studies. TB-500 (a synthetic fragment of thymosin beta-4) similarly shows wound healing and regenerative effects in animal models. KLOW, a peptide complex used in some veterinary and sports medicine contexts, has animal data but no human trials. None of these three have published human clinical trial data. The animal results are interesting enough that they are hard to dismiss, but translating rodent studies to humans has failed repeatedly across pharmacology. You are making a bet when you use any of them.

Speculative and emerging. GHK-Cu (copper peptide), Epithalon, and Dihexa fall into this category. Epithalon supposedly activates telomerase and extends telomere length in cell studies and some animal work. The connection to meaningful human longevity outcomes is essentially zero. GHK-Cu has cell culture data for wound healing and some animal evidence. Dihexa is a neuroprotective peptide with rodent cognitive data. None of these have human trials to point to. Using them is pure experimentation.

What “research use only” actually means. Suppliers selling gray-market peptides typically label them as “research use only, not for human consumption.” This is legal cover, not a quality statement. It means the compound hasn’t been approved for human use, the supplier is not regulated as a pharmacy, and there is no oversight of what’s actually in the vial. The label protects the seller. It does nothing for you.

Growth Hormone Releasing Peptides

The most commonly used peptides in biohacking fall into two categories: GHRH analogs (like CJC-1295 and Sermorelin) and ghrelin mimetics or GHRPs (like Ipamorelin and GHRP-6).

GHRH analogs tell the pituitary to secrete growth hormone. Ghrelin mimetics act on GH secretagogue receptors in the pituitary through a different mechanism. Combining them (the “stack” approach) is common because they work through different pathways and have an additive effect on GH release.

The human evidence for GH elevation from CJC-1295 plus Ipamorelin is real but limited. Studies show pulsatile GH increases and downstream IGF-1 elevation. What’s not established: whether elevated GH and IGF-1 from peptides produces meaningful improvements in body composition, recovery, or aging outcomes in healthy people without GH deficiency.

The IGF-1 issue deserves explicit attention. Elevated IGF-1 drives muscle and cell growth, which sounds appealing. But there is a paradox. Observational data in humans shows that people with naturally lower IGF-1 (within normal range) tend to live longer, and IGF-1 pathway mutations in centenarian populations point toward lower signaling as longevity-protective. Animals with IGF-1 pathway downregulation (like dwarf mice) live significantly longer. This doesn’t mean GH peptides will harm you, but the “more IGF-1 equals anti-aging” narrative is not supported by the longevity literature. If you’re using these peptides for performance or recovery in the short term, that’s a different calculation. If you’re using them specifically for longevity, the evidence works against you.

Typical administration is subcutaneous injection, usually before bed to sync with natural GH pulses. Side effects include water retention, tingling or numbness (common with GHRP-6), and increased appetite. GHRP-6 is notably appetite-stimulating, which is why Ipamorelin is often preferred by people not trying to eat more.

BPC-157 and TB-500

These get their own section because they dominate biohacking discussions, but proportionate treatment means acknowledging: the evidence is animal only, and the human data simply doesn’t exist yet.

BPC-157 (body protective compound-157) is derived from a protein found in gastric juice. The rodent literature is extensive: accelerated tendon and ligament healing, gut mucosal repair, CNS protective effects, reduced inflammation. The mechanisms proposed involve nitric oxide signaling and angiogenesis promotion. It’s a genuinely interesting compound.

TB-500 is a synthetic version of thymosin beta-4, a protein involved in actin regulation and wound healing. It shows tissue repair effects in animal models and has some legitimate veterinary use.

The reason people use them: the animal results are consistent enough to be credible, and anecdotal reports from people who’ve injected them are often positive. The risk profile in animals is low. But you’re extrapolating from rodents to humans without a clinical bridge, buying from unregulated suppliers, and injecting something with unknown purity into your body. That’s the actual situation. Whether that tradeoff is acceptable is your call, not a scientific question.

Peptide Therapy for Longevity

The longevity peptide category (Epithalon, GHK-Cu, Dihexa) is where the evidence gets thinnest and the marketing gets loudest.

Epithalon is a tetrapeptide studied primarily by Russian researchers since the 1980s, with claims around telomere extension and cancer prevention. The research exists but hasn’t been replicated by independent groups and doesn’t meet current clinical evidence standards. The telomere claims are particularly speculative: even if a compound increases telomere length in cell culture, that doesn’t translate to extended healthy lifespan. Telomere biology is considerably more complex.

GHK-Cu (copper peptide) has more interesting biology. It activates skin repair, wound healing, and has shown anti-inflammatory effects in cell studies. It’s used topically in cosmetics with some evidence for skin improvement. Systemic injectable use is another question entirely.

The IGF-1 paradox mentioned earlier applies directly here: many longevity pathways (mTOR inhibition, caloric restriction effects, FOXO pathway activation) work by reducing growth signals, not increasing them. If you’re using GH-releasing peptides for longevity, you’re working against some of the best-supported longevity mechanisms in the research literature.

Worth watching: GLP-1 peptides (the same class as semaglutide and liraglutide) are producing surprising longevity-adjacent findings in metabolic disease, neurodegeneration risk, and cardiac outcomes. That’s the peptide story that actually has human data right now, though the longevity implications are still being worked out.

The Sourcing Problem

If you take one thing from this article, make it this: the peptide you buy online is only as good as the supplier’s quality control, which is essentially nonexistent. That’s the single most important fact about peptide therapies.

There are two sourcing paths.

Compounding pharmacies. Legitimate pharmacies can compound peptides with a valid prescription. Sermorelin and some other peptides can be obtained this way. These are subject to state pharmacy board oversight, have quality standards, and involve physician involvement. This is the appropriate sourcing path if you’re serious about peptide therapy.

Research chemical suppliers. This is where most online purchases happen. These are unregulated businesses selling peptides labeled as “for research purposes.” Independent testing has repeatedly found: dosing accuracy well below labeled content, bacterial contamination, mislabeled compounds, and presence of unknown impurities.

Analyses of commercially available BPC-157 and TB-500 have found significant concentration errors and purity issues across multiple suppliers. This is not an edge case. It is the norm. The compound might work; what’s in the vial might not be that compound.

Third-party testing exists and matters. Some suppliers submit to independent labs and publish HPLC analysis results. This is meaningful but insufficient. A single lot test doesn’t guarantee consistency across batches. If you’re buying gray market, look for suppliers who publish batch-specific third-party testing, not just a general purity certificate. Community reputation changes over time and isn’t a substitute for testing data.

The legal exposure is real. Possession and importation of research peptides exists in a gray zone in most jurisdictions. It’s not equivalent to controlled substance risk, but it’s not clean either. Understand what you’re accepting.

Who Should Consider Peptide Therapy

Legitimate use cases with medical supervision. Growth hormone deficiency diagnosed by an endocrinologist is the clearest case, where sermorelin or a similar prescribed peptide is appropriate. Injury recovery under physician supervision in a clinical setting is another. Specific medical conditions where approved peptide medications are indicated (diabetes, obesity management with GLP-1 analogs) are straightforward.

The biohacking use case. If you’re a healthy person without a diagnosed condition seeking enhancement or anti-aging effects, the honest position is: you’re running an experiment with limited human evidence, from an unregulated supply chain, for outcomes that may take years to evaluate. Some people do this knowingly and accept that tradeoff. That’s a legitimate choice. Go in with clear eyes, not marketing copy in your head.

Who should skip it. Anyone with a history of cancer or elevated cancer risk should be especially cautious about compounds that raise IGF-1 or promote cell proliferation. Pregnant women, anyone on hormone therapies, and people with active medical conditions should talk to a physician before considering any peptide.

On anti-aging clinics. Many “peptide therapy” clinics operate on a functional or regenerative medicine model. Some are run by physicians with genuine expertise in endocrinology and longevity medicine. Others are wellness business models with minimal clinical depth. Ask who is prescribing, what their credentials are, what monitoring is included, and what evidence base they’re working from. A clinic that can’t tell you the specific studies behind their protocol is a clinic optimized for sales.

Frequently Asked Questions

What peptides have the best evidence? FDA-approved peptides prescribed for their indicated uses (sermorelin for GH deficiency, liraglutide for metabolic disease) have the strongest evidence. CJC-1295 and Ipamorelin have human pharmacological data. BPC-157 and TB-500 have strong animal evidence but no human trials to point to.

Are peptide therapies safe? The approved ones, used as prescribed, have established safety profiles. Gray-market peptides have an unknown safety profile because sourcing is unregulated. The compound may be safe; what’s in the vial may not be.

How are peptides administered? Most require subcutaneous injection because oral bioavailability is poor. Some are available as nasal sprays or topical preparations. Injectable peptides require sterile technique and proper storage. Many require refrigeration and have limited stability once reconstituted.

What does peptide therapy cost? Through a clinic with physician oversight: typically $150 to $500 per month depending on the peptide and protocol. Through gray-market suppliers: $50 to $150 per month for most compounds. The price difference reflects regulatory overhead and physician involvement, not necessarily a difference in the molecule.

Do I need a prescription for peptides? For compounding pharmacy sourcing, yes. For gray-market purchases, the answer is legally complicated and jurisdiction-dependent. Practically, no prescription is required from online suppliers. That is also why quality control is absent.

What is the difference between peptide hormones and steroids? Steroids are lipid-based molecules (cholesterol-derived) that typically affect gene expression directly by crossing the cell membrane and binding to nuclear receptors. Peptide hormones are amino acid chains that bind to surface receptors and trigger intracellular signaling cascades. They have different mechanisms, different synthesis pathways, and different regulatory status. Anabolic steroids are Schedule III controlled substances in the US; most research peptides are not scheduled but are regulated differently under FDA frameworks.